113 related articles for article (PubMed ID: 37574339)
1. Cost and effectiveness analyses of the anti-osteoporosis medication in patients with hip fracture in Taiwan: A population-based national claims database analysis.
Wang CY; Wu CH; Chen HM; Lin JW; Hsu CC; Chang YF; Tai TW; Fu SH; Hwang JS
J Formos Med Assoc; 2023; 122 Suppl 1():S92-S100. PubMed ID: 37574339
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness of anti-osteoporosis medications for the prevention of incident hip and clinical vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan.
Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Kamiya K; Ogawa S
Bone; 2023 Jan; 166():116605. PubMed ID: 36347433
[TBL] [Abstract][Full Text] [Related]
3. Impact of the Requirement of Bone Mineral Density Evidence on Utilization of Anti-osteoporosis Medications, Clinical Outcome and Medical Expenditures of Patient With Hip Fracture in Taiwan.
Wang CY; Fu SH; Hung CC; Yang RS; Lin JW; Chen HM; Hsiao FY; Shen LJ
Int J Health Policy Manag; 2022 Apr; 11(4):470-478. PubMed ID: 33059424
[TBL] [Abstract][Full Text] [Related]
4. Delayed initiation of anti-osteoporosis medications increases subsequent hip and vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan.
Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Kamiya K; Ogawa S
Bone; 2022 Jul; 160():116396. PubMed ID: 35351673
[TBL] [Abstract][Full Text] [Related]
5. Timing of anti-osteoporosis medications initiation after a hip fracture affects the risk of subsequent fracture: A nationwide cohort study.
Wang CY; Fu SH; Yang RS; Chen LK; Shen LJ; Hsiao FY
Bone; 2020 Sep; 138():115452. PubMed ID: 32464276
[TBL] [Abstract][Full Text] [Related]
6. Eleven years secular trend of the initiation of anti-osteoporosis medications and subsequent fractures in Taiwan: From 2008 to 2018.
Yang TH; Wang CY; Fu SH; Chan DC; Chen HM; Lin JW; Huang CF; Yang JJ; Wu CH; Hwang JS; Yang RS
J Formos Med Assoc; 2023; 122 Suppl 1():S36-S44. PubMed ID: 37280138
[TBL] [Abstract][Full Text] [Related]
7. Visualisation of the unmet treatment need of osteoporotic fracture in Taiwan: A nationwide cohort study.
Wang CY; Fu SH; Huang CC; Hung CC; Yang RS; Hsiao FY
Int J Clin Pract; 2018 Oct; 72(10):e13246. PubMed ID: 30144247
[TBL] [Abstract][Full Text] [Related]
8. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
[TBL] [Abstract][Full Text] [Related]
9. Effects of anti-osteoporosis medications on total hip arthroplasty risks in osteoporotic patients with hip osteoarthritis in Taiwan: a nationwide cohort study.
Hung CC; Wang CY; Fu SH; Yang RS; Hsiao FY
Arch Osteoporos; 2018 Oct; 13(1):107. PubMed ID: 30306268
[TBL] [Abstract][Full Text] [Related]
10. Comparative Interrupted Time Series Analysis of Long-term Direct Medical Costs in Patients With Hip Fractures and a Matched Cohort: A Large-database Study.
Jang SY; Lee JW; Kim KJ; Kim HY; Choy WS; Cha Y
Clin Orthop Relat Res; 2022 May; 480(5):891-902. PubMed ID: 34807010
[TBL] [Abstract][Full Text] [Related]
11. Treatment patterns of long-dose-interval medication for persistent management of osteoporosis in Taiwan.
Lin SY; Chen YM; Chen WJ; Li CY; Ku CK; Chen CH; Chien LN
Arch Osteoporos; 2022 Jul; 17(1):94. PubMed ID: 35840845
[TBL] [Abstract][Full Text] [Related]
12. Increased risk of hip fractures in patients with dementia: a nationwide population-based study.
Wang HK; Hung CM; Lin SH; Tai YC; Lu K; Liliang PC; Lin CW; Lee YC; Fang PH; Chang LC; Li YC
BMC Neurol; 2014 Sep; 14():175. PubMed ID: 25213690
[TBL] [Abstract][Full Text] [Related]
13. The association between osteoporosis medications and lowered all-cause mortality after hip or vertebral fracture in older and oldest-old adults: a nationwide population-based study.
Li CC; Hsu JC; Liang FW; Chang YF; Chiu CJ; Wu CH
Aging (Albany NY); 2022 Mar; 14(5):2239-2251. PubMed ID: 35232893
[TBL] [Abstract][Full Text] [Related]
14. The real-world adherence of the first-line anti-osteoporosis medications in Taiwan: Visualize the gap between reality and expectations.
Lee CC; Fu SH; Chen HM; Lin JW; Hsu CC; Lin SC; Hwang JS; Yang RS; Wu CH; Wang CY
J Formos Med Assoc; 2023; 122 Suppl 1():S55-S64. PubMed ID: 37302970
[TBL] [Abstract][Full Text] [Related]
15. Access to Anti-osteoporosis Medication after Hip Fracture in Korean Elderly Patients.
Yu YM; Lee JY; Lee E
Maturitas; 2017 Sep; 103():54-59. PubMed ID: 28778333
[TBL] [Abstract][Full Text] [Related]
16. The mortality and direct medical costs of osteoporotic fractures among postmenopausal women in Taiwan.
Chang CY; Tang CH; Chen KC; Huang KC; Huang KC
Osteoporos Int; 2016 Feb; 27(2):665-76. PubMed ID: 26243356
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and Cost of Subsequent Fractures Among U.S. Patients with an Incident Fracture.
Weaver J; Sajjan S; Lewiecki EM; Harris ST; Marvos P
J Manag Care Spec Pharm; 2017 Apr; 23(4):461-471. PubMed ID: 28345441
[TBL] [Abstract][Full Text] [Related]
18. A national study on long-term osteoporosis therapy and risk of recurrent fractures in patients with hip fracture.
Hsu CL; Chen HM; Chen HJ; Chou MY; Wang YC; Hsu YH; Liang CK; Chu CS
Arch Gerontol Geriatr; 2020; 88():104021. PubMed ID: 32058125
[TBL] [Abstract][Full Text] [Related]
19. Real-world cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in Taiwan.
Johnson B; Lai EC; Ou HT; Li H; Stollenwerk B
Arch Osteoporos; 2021 Oct; 16(1):155. PubMed ID: 34636982
[TBL] [Abstract][Full Text] [Related]
20. Constraining in reimbursement criteria and the adherence to anti-osteoporosis medications (AOMs) in Taiwan: Urbanization makes the difference.
Wang CY; Yang TH; Fu SH; Hwang JS; Chen HM; Lin JW; Hsu CC; Chang YF; Wu CH; Chan DC; Yang RS
J Formos Med Assoc; 2023; 122 Suppl 1():S45-S54. PubMed ID: 37271714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
